- Home
- NTIP vs NRXS Comparison
NTIP vs NRXS Comparison
Compare NTIP & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- NRXS
- Stock Information
- Founded
- NTIP 1990
- NRXS 2011
- Country
- NTIP United States
- NRXS United States
- Employees
- NTIP N/A
- NRXS N/A
- Industry
- NTIP Multi-Sector Companies
- NRXS
- Sector
- NTIP Miscellaneous
- NRXS
- Exchange
- NTIP Nasdaq
- NRXS Nasdaq
- Market Cap
- NTIP 32.0M
- NRXS 25.8M
- IPO Year
- NTIP 1998
- NRXS 2023
- Fundamental
- Price
- NTIP $1.50
- NRXS $3.02
- Analyst Decision
- NTIP
- NRXS Strong Buy
- Analyst Count
- NTIP 0
- NRXS 1
- Target Price
- NTIP N/A
- NRXS $7.00
- AVG Volume (30 Days)
- NTIP 9.7K
- NRXS 1.1M
- Earning Date
- NTIP 10-24-2025
- NRXS 11-12-2025
- Dividend Yield
- NTIP 6.67%
- NRXS N/A
- EPS Growth
- NTIP N/A
- NRXS N/A
- EPS
- NTIP N/A
- NRXS N/A
- Revenue
- NTIP $150,000.00
- NRXS $3,217,531.00
- Revenue This Year
- NTIP N/A
- NRXS $62.14
- Revenue Next Year
- NTIP N/A
- NRXS $131.87
- P/E Ratio
- NTIP N/A
- NRXS N/A
- Revenue Growth
- NTIP N/A
- NRXS 41.93
- 52 Week Low
- NTIP $1.16
- NRXS $1.33
- 52 Week High
- NTIP $1.90
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- NTIP 46.75
- NRXS 46.34
- Support Level
- NTIP $1.48
- NRXS $2.94
- Resistance Level
- NTIP $1.54
- NRXS $3.96
- Average True Range (ATR)
- NTIP 0.04
- NRXS 0.33
- MACD
- NTIP -0.00
- NRXS -0.06
- Stochastic Oscillator
- NTIP 17.56
- NRXS 15.32
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).